Combined GWAS and 'Guilt by Association'-Based Prioritization Analysis Identifies Functional Candidate Genes for Body Size
Total Page:16
File Type:pdf, Size:1020Kb
Load more
Recommended publications
-
Datasheet PDF (RUO)
BioVendor - Laboratorní medicína a.s. Karásek 1767/1 621 00 Brno-Řečkovice a Mokrá Hora Date of issue: 05.01.2021 PRODUCT DATASHEET Stanniocalcin 2 Human HEK293 Cat. No.: RD172096100 Type: Recombinant protein Size: 0.1 mg Source: HEK293 Species: Human Description Total 289 AA. Mw: 31.9 kDa (calculated). C-Terminal Flag-tag, 12AA (highlighted). The AA sequence is identical to Swiss-Prot- O76061 (STC2, aa 25–302). Other names Stanniocalcin-related protein, STC-related protein, STCRP, STC2 Introduction to the molecule Stanniocalcin 2 (STC2) is a secreted, homodimeric glycoprotein that is expressed in a wide variety of tissues including muscle, heart, pancreas, kidney, spleen, prostate, small intestine, colon and peripheral blood leukocytes. The encoded protein has 10 of its 15 cysteine residues conserved among stanniocalcin family members and is phosphorylated by casein kinase 2 exclusively on its serine residues. Its C-terminus contains a cluster of histidine residues which may interact with metal ions. STC2 may have autocrine or paracrine functions. The protein may play a role in the regulation of renal and intestinal calcium and phosphate transport, cell metabolism, or cellular calcium/phosphate homeostasis. Constitutive overexpression of human stanniocalcin 2 in mice resulted in pre- and postnatal growth restriction, reduced bone and skeletal muscle growth, and organomegaly. STC2 is also known to be involved in the regulation of unfolded protein response in the endoplasmic reticulum (ER), as well as in the regulation of cell proliferation under hypoxic conditions. In addition, a series of recent studies have shown that STC2 is also associated with cancer development. The expression of STC2 is up-regulated in several cancer types, including gastric cancer, neuroblastoma, colon cancer, prostate cancer and breast cancer. -
4-6 Weeks Old Female C57BL/6 Mice Obtained from Jackson Labs Were Used for Cell Isolation
Methods Mice: 4-6 weeks old female C57BL/6 mice obtained from Jackson labs were used for cell isolation. Female Foxp3-IRES-GFP reporter mice (1), backcrossed to B6/C57 background for 10 generations, were used for the isolation of naïve CD4 and naïve CD8 cells for the RNAseq experiments. The mice were housed in pathogen-free animal facility in the La Jolla Institute for Allergy and Immunology and were used according to protocols approved by the Institutional Animal Care and use Committee. Preparation of cells: Subsets of thymocytes were isolated by cell sorting as previously described (2), after cell surface staining using CD4 (GK1.5), CD8 (53-6.7), CD3ε (145- 2C11), CD24 (M1/69) (all from Biolegend). DP cells: CD4+CD8 int/hi; CD4 SP cells: CD4CD3 hi, CD24 int/lo; CD8 SP cells: CD8 int/hi CD4 CD3 hi, CD24 int/lo (Fig S2). Peripheral subsets were isolated after pooling spleen and lymph nodes. T cells were enriched by negative isolation using Dynabeads (Dynabeads untouched mouse T cells, 11413D, Invitrogen). After surface staining for CD4 (GK1.5), CD8 (53-6.7), CD62L (MEL-14), CD25 (PC61) and CD44 (IM7), naïve CD4+CD62L hiCD25-CD44lo and naïve CD8+CD62L hiCD25-CD44lo were obtained by sorting (BD FACS Aria). Additionally, for the RNAseq experiments, CD4 and CD8 naïve cells were isolated by sorting T cells from the Foxp3- IRES-GFP mice: CD4+CD62LhiCD25–CD44lo GFP(FOXP3)– and CD8+CD62LhiCD25– CD44lo GFP(FOXP3)– (antibodies were from Biolegend). In some cases, naïve CD4 cells were cultured in vitro under Th1 or Th2 polarizing conditions (3, 4). -
Human Receptor-Interacting Serine/Threonine-Protein Kinase 2 (RIPK2) a Target Enabling Package (TEP)
Human Receptor-Interacting Serine/Threonine-Protein Kinase 2 (RIPK2) A Target Enabling Package (TEP) Gene ID / UniProt ID / EC 8767 / O43353 / - Target Nominator SGC Internal Nomination SGC Authors Peter Canning, Daniel M. Pinkas, Joshua C. Bufton, Sarah Picaud, Jennifer A. Ward, Catherine Rogers, Benedict-Tilman Berger, Stefan Knapp, Susanne Muller-Knapp, Paul E. Brennan, Kilian V. M. Huber, Panagis Filippakopoulos, Alex N. Bullock Collaborating Authors Matous Hrdinka1, Qui Ruan2, Chalada Suebsuwong3, Lisa Schlicher1, Bing Dai2, Jenny L. Maki2, Soumya S. Ray4, Danish Saleh5, Sameer Nikhar6, Tobias Schwerd7, Holm H.Uhlig7, Gregory D. Cuny6, Alexei Degterev2, Mads Gyrd-Hansen1 Target PI Alex N. Bullock (SGC Oxford) Therapeutic Area(s) Inflammatory diseases Disease Relevance Mutations in the NOD2-RIPK2 pathway identify RIPK2 a potential therapeutic target in auto-immune and inflammatory conditions such as Crohn’s disease, Blau syndrome, early-onset osteoarthritis and multiple sclerosis. Date Approved by TEP Evaluation 13th June 2018 Group Document version Version 3 Document version date October 2020 Citation Peter Canning, Daniel M. Pinkas, Joshua C. Bufton, Sarah Picaud, Jennifer A. Ward, Catherine Rogers, … Alex N. Bullock. (2018). Human Receptor- Interacting Serine/Threonine-Protein Kinase 2 (RIPK2); A Target Enabling Package. Zenodo. http://doi.org/10.5281/zenodo.1344501 Affiliations 1. Ludwig Institute for Cancer Research, Nuffield Department of Clinical Medicine, University of Oxford 2. Department of Developmental, Molecular & Chemical Biology, Tufts University School of Medicine 3. Department of Chemistry, Science and Research Building 2, University of Houston 4. Center for Neurologic Diseases, Department of Neurology, Brigham & Women's Hospital and Harvard Medical School 5. Medical Scientist Training Program and Program in Neuroscience, Sackler School of Graduate Biomedical Sciences, Tufts University School of Medicine 6. -
Concomitant DNA Methylation and Transcriptome Signatures Define
www.nature.com/scientificreports OPEN Concomitant DNA methylation and transcriptome signatures defne epidermal responses to acute solar UV radiation Nicholas Holzscheck 1,2*, Jörn Söhle 1, Torsten Schläger1, Cassandra Falckenhayn 1, Elke Grönniger 1, Ludger Kolbe 1, Horst Wenck 1, Lara Terstegen1, Lars Kaderali 2, Marc Winnefeld 1 & Katharina Gorges1* The simultaneous analysis of diferent regulatory levels of biological phenomena by means of multi-omics data integration has proven an invaluable tool in modern precision medicine, yet many processes ultimately paving the way towards disease manifestation remain elusive and have not been studied in this regard. Here we investigated the early molecular events following repetitive UV irradiation of in vivo healthy human skin in depth on transcriptomic and epigenetic level. Our results provide frst hints towards an immediate acquisition of epigenetic memories related to aging and cancer and demonstrate signifcantly correlated epigenetic and transcriptomic responses to irradiation stress. The data allowed the precise prediction of inter-individual UV sensitivity, and molecular subtyping on the integrated post-irradiation multi-omics data established the existence of three latent molecular phototypes. Importantly, further analysis suggested a form of melanin-independent DNA damage protection in subjects with higher innate UV resilience. This work establishes a high- resolution molecular landscape of the acute epidermal UV response and demonstrates the potential of integrative analyses to untangle complex and heterogeneous biological responses. Solar UV irradiation has complex and ambivalent efects on the human organism. Benefcial efects of sun expo- sure are thought to be mainly mediated by vitamin D, which is synthesized in the skin through a photosynthetic reaction triggered by exposure to UVB. -
Systems Consequences of Amplicon Formation in Human Breast Cancer
Downloaded from genome.cshlp.org on September 25, 2021 - Published by Cold Spring Harbor Laboratory Press Research Systems consequences of amplicon formation in human breast cancer Koichiro Inaki,1,2,9 Francesca Menghi,1,2,9 Xing Yi Woo,1,9 Joel P. Wagner,1,2,3 4,5 1 2 Pierre-Etienne Jacques, Yi Fang Lee, Phung Trang Shreckengast, Wendy WeiJia Soon,1 Ankit Malhotra,2 Audrey S.M. Teo,1 Axel M. Hillmer,1 Alexis Jiaying Khng,1 Xiaoan Ruan,6 Swee Hoe Ong,4 Denis Bertrand,4 Niranjan Nagarajan,4 R. Krishna Murthy Karuturi,4,7 Alfredo Hidalgo Miranda,8 andEdisonT.Liu1,2,7 1Cancer Therapeutics and Stratified Oncology, Genome Institute of Singapore, Genome, Singapore 138672, Singapore; 2The Jackson Laboratory for Genomic Medicine, Farmington, Connecticut 06030, USA; 3Department of Biological Engineering, Massachusetts Institute of Technology, Cambridge, Massachusetts 02139, USA; 4Computational and Systems Biology, Genome Institute of Singapore, Genome, Singapore 138672, Singapore; 5Universite de Sherbrooke, Sherbrooke, Quebec, J1K 2R1, Canada; 6Genome Technology and Biology, Genome Institute of Singapore, Genome, Singapore 138672, Singapore; 7The Jackson Laboratory, Bar Harbor, Maine 04609, USA; 8National Institute of Genomic Medicine, Periferico Sur 4124, Mexico City 01900, Mexico Chromosomal structural variations play an important role in determining the transcriptional landscape of human breast cancers. To assess the nature of these structural variations, we analyzed eight breast tumor samples with a focus on regions of gene amplification using mate-pair sequencing of long-insert genomic DNA with matched transcriptome profiling. We found that tandem duplications appear to be early events in tumor evolution, especially in the genesis of amplicons. -
Transcriptome Analysis of Human Diabetic Kidney Disease
ORIGINAL ARTICLE Transcriptome Analysis of Human Diabetic Kidney Disease Karolina I. Woroniecka,1 Ae Seo Deok Park,1 Davoud Mohtat,2 David B. Thomas,3 James M. Pullman,4 and Katalin Susztak1,5 OBJECTIVE—Diabetic kidney disease (DKD) is the single cases, mild and then moderate mesangial expansion can be leading cause of kidney failure in the U.S., for which a cure has observed. In general, diabetic kidney disease (DKD) is not yet been found. The aim of our study was to provide an considered a nonimmune-mediated degenerative disease unbiased catalog of gene-expression changes in human diabetic of the glomerulus; however, it has long been noted that kidney biopsy samples. complement and immunoglobulins sometimes can be de- — tected in diseased glomeruli, although their role and sig- RESEARCH DESIGN AND METHODS Affymetrix expression fi arrays were used to identify differentially regulated transcripts in ni cance is not clear (4). 44 microdissected human kidney samples. The DKD samples were The understanding of DKD has been challenged by multi- significant for their racial diversity and decreased glomerular ple issues. First, the diagnosis of DKD usually is made using filtration rate (~20–30 mL/min). Stringent statistical analysis, using clinical criteria, and kidney biopsy often is not performed. the Benjamini-Hochberg corrected two-tailed t test, was used to According to current clinical practice, the development of identify differentially expressed transcripts in control and diseased albuminuria in patients with diabetes is sufficient to make the glomeruli and tubuli. Two different Web-based algorithms were fi diagnosis of DKD (5). We do not understand the correlation used to de ne differentially regulated pathways. -
Macrophage Activation JUNB Is a Key Transcriptional Modulator Of
JUNB Is a Key Transcriptional Modulator of Macrophage Activation Mary F. Fontana, Alyssa Baccarella, Nidhi Pancholi, Miles A. Pufall, De'Broski R. Herbert and Charles C. Kim This information is current as of October 2, 2021. J Immunol 2015; 194:177-186; Prepublished online 3 December 2014; doi: 10.4049/jimmunol.1401595 http://www.jimmunol.org/content/194/1/177 Downloaded from Supplementary http://www.jimmunol.org/content/suppl/2014/12/03/jimmunol.140159 Material 5.DCSupplemental References This article cites 40 articles, 7 of which you can access for free at: http://www.jimmunol.org/content/194/1/177.full#ref-list-1 http://www.jimmunol.org/ Why The JI? Submit online. • Rapid Reviews! 30 days* from submission to initial decision • No Triage! Every submission reviewed by practicing scientists by guest on October 2, 2021 • Fast Publication! 4 weeks from acceptance to publication *average Subscription Information about subscribing to The Journal of Immunology is online at: http://jimmunol.org/subscription Permissions Submit copyright permission requests at: http://www.aai.org/About/Publications/JI/copyright.html Email Alerts Receive free email-alerts when new articles cite this article. Sign up at: http://jimmunol.org/alerts The Journal of Immunology is published twice each month by The American Association of Immunologists, Inc., 1451 Rockville Pike, Suite 650, Rockville, MD 20852 Copyright © 2014 by The American Association of Immunologists, Inc. All rights reserved. Print ISSN: 0022-1767 Online ISSN: 1550-6606. The Journal of Immunology JUNB Is a Key Transcriptional Modulator of Macrophage Activation Mary F. Fontana,* Alyssa Baccarella,* Nidhi Pancholi,* Miles A. -
Bioinformatics Integrated Analysis to Investigate Candidate Biomarkers and Associated Metabolites in Osteosarcoma
Wang et al. Journal of Orthopaedic Surgery and Research (2021) 16:432 https://doi.org/10.1186/s13018-021-02578-0 RESEARCH ARTICLE Open Access Bioinformatics integrated analysis to investigate candidate biomarkers and associated metabolites in osteosarcoma Jun Wang, Mingzhi Gong, Zhenggang Xiong, Yangyang Zhao and Deguo Xing* Abstract Background: This study hoped to explore the potential biomarkers and associated metabolites during osteosarcoma (OS) progression based on bioinformatics integrated analysis. Methods: Gene expression profiles of GSE28424, including 19 human OS cell lines (OS group) and 4 human normal long bone tissue samples (control group), were downloaded. The differentially expressed genes (DEGs) in OS vs. control were investigated. The enrichment investigation was performed based on DEGs, followed by protein–protein interaction network analysis. Then, the feature genes associated with OS were explored, followed by survival analysis to reveal prognostic genes. The qRT-PCR assay was performed to test the expression of these genes. Finally, the OS- associated metabolites and disease-metabolic network were further investigated. Results: Totally, 357 DEGs were revealed between the OS vs. control groups. These DEGs, such as CXCL12, were mainly involved in functions like leukocyte migration. Then, totally, 38 feature genes were explored, of which 8 genes showed significant associations with the survival of patients. High expression of CXCL12, CEBPA, SPARCL1, CAT, TUBA1A, and ALDH1A1 was associated with longer survival time, while high expression of CFLAR and STC2 was associated with poor survival. Finally, a disease-metabolic network was constructed with 25 nodes including two disease-associated metabolites cyclophosphamide and bisphenol A (BPA). BPA showed interactions with multiple prognosis-related genes, such as CXCL12 and STC2. -
Targeting RIP Kinases in Chronic Inflammatory Disease
biomolecules Review Targeting RIP Kinases in Chronic Inflammatory Disease Mary Speir 1,2, Tirta M. Djajawi 1,2 , Stephanie A. Conos 1,2, Hazel Tye 1 and Kate E. Lawlor 1,2,* 1 Centre for Innate Immunity and Infectious Diseases, Hudson Institute of Medical Research, Clayton, VIC 3168, Australia; [email protected] (M.S.); [email protected] (T.M.D.); [email protected] (S.A.C.); [email protected] (H.T.) 2 Department of Molecular and Translational Science, Monash University, Clayton, VIC 3168, Australia * Correspondence: [email protected]; Tel.: +61-85722700 Abstract: Chronic inflammatory disorders are characterised by aberrant and exaggerated inflam- matory immune cell responses. Modes of extrinsic cell death, apoptosis and necroptosis, have now been shown to be potent drivers of deleterious inflammation, and mutations in core repressors of these pathways underlie many autoinflammatory disorders. The receptor-interacting protein (RIP) kinases, RIPK1 and RIPK3, are integral players in extrinsic cell death signalling by regulating the production of pro-inflammatory cytokines, such as tumour necrosis factor (TNF), and coordinating the activation of the NOD-like receptor protein 3 (NLRP3) inflammasome, which underpin patholog- ical inflammation in numerous chronic inflammatory disorders. In this review, we firstly give an overview of the inflammatory cell death pathways regulated by RIPK1 and RIPK3. We then discuss how dysregulated signalling along these pathways can contribute to chronic inflammatory disorders of the joints, skin, and gastrointestinal tract, and discuss the emerging evidence for targeting these RIP kinases in the clinic. Keywords: apoptosis; necroptosis; RIP kinases; chronic inflammatory disease; tumour necrosis factor; Citation: Speir, M.; Djajawi, T.M.; interleukin-1 Conos, S.A.; Tye, H.; Lawlor, K.E. -
CD29 Identifies IFN-Γ–Producing Human CD8+ T Cells with an Increased Cytotoxic Potential
+ CD29 identifies IFN-γ–producing human CD8 T cells with an increased cytotoxic potential Benoît P. Nicoleta,b, Aurélie Guislaina,b, Floris P. J. van Alphenc, Raquel Gomez-Eerlandd, Ton N. M. Schumacherd, Maartje van den Biggelaarc,e, and Monika C. Wolkersa,b,1 aDepartment of Hematopoiesis, Sanquin Research, 1066 CX Amsterdam, The Netherlands; bLandsteiner Laboratory, Oncode Institute, Amsterdam University Medical Center, University of Amsterdam, 1105 AZ Amsterdam, The Netherlands; cDepartment of Research Facilities, Sanquin Research, 1066 CX Amsterdam, The Netherlands; dDivision of Molecular Oncology and Immunology, Oncode Institute, The Netherlands Cancer Institute, 1066 CX Amsterdam, The Netherlands; and eDepartment of Molecular and Cellular Haemostasis, Sanquin Research, 1066 CX Amsterdam, The Netherlands Edited by Anjana Rao, La Jolla Institute for Allergy and Immunology, La Jolla, CA, and approved February 12, 2020 (received for review August 12, 2019) Cytotoxic CD8+ T cells can effectively kill target cells by producing therefore developed a protocol that allowed for efficient iso- cytokines, chemokines, and granzymes. Expression of these effector lation of RNA and protein from fluorescence-activated cell molecules is however highly divergent, and tools that identify and sorting (FACS)-sorted fixed T cells after intracellular cytokine + preselect CD8 T cells with a cytotoxic expression profile are lacking. staining. With this top-down approach, we performed an un- + Human CD8 T cells can be divided into IFN-γ– and IL-2–producing biased RNA-sequencing (RNA-seq) and mass spectrometry cells. Unbiased transcriptomics and proteomics analysis on cytokine- γ– – + + (MS) analyses on IFN- and IL-2 producing primary human producing fixed CD8 T cells revealed that IL-2 cells produce helper + + + CD8 Tcells. -
Identification of NTN4, TRA1, and STC2 As Prognostic Markers in Breast Cancer in a Screen for Signal Sequence Encoding Proteins
Human Cancer Biology Identification of NTN4, TRA1,andSTC2 as Prognostic Markers in Breast Cancer in a Screen for Signal Sequence Encoding Proteins Selma Esseghir,1Alan Kennedy,1Pooja Seedhar,2 Ashutosh Nerurkar,3 Richard Poulsom,2 Jorge S. Reis-Filho,1and Clare M. Isacke1 Abstract Purpose: In a previous screen using a signal-trap library, we identified a number of secreted pro- teins up-regulated in primary tumor cells isolated from invasive breast cancers.The purpose of this study was to assess the expression of these genes in human invasive breast tumors and to deter- mine the significance of their expression for prognosis in breast cancer. Experimental Design: A tissue microarray containing 245 invasive breast tumors from women treated with curative surgery followed by anthracycline-based chemotherapy and hormone ther- apy for the estrogen receptor (ER)^ positive tumors was screened by in situ hybridization with probes against thrombospondin 3 (TSP3), insulin-like growth factor binding protein 7 (IGFBP7), tumor rejection antigen 1 (TRA1), stanniocalcin 2 (STC2),andnetrin4(NTN4). Correlations be- tween categorical variables were done using the m2 test and Fisher’s exact test. Cumulative sur- vival probabilities were calculated using the Kaplan-Meier method and multivariate survival analysis was done with Cox hazard model. A series of breast cancers were also stained with NTN4 antibodies. Results: All five genes examined were expressed in invasive breast tumor cells. NTN4 protein expression was also confirmed by immunohistochemistry.Together, these data validate the design and screening of the signal-trap library. Univariate survival analysis revealed that expressions of TRA1, STC2 ,andNTN4 are correlated with longer disease-free survival and thatTRA1 and NTN4 are associated with longer overall survival. -
Integrative Analysis of Transcriptomic Data for Identification of T-Cell
www.nature.com/scientificreports OPEN Integrative analysis of transcriptomic data for identifcation of T‑cell activation‑related mRNA signatures indicative of preterm birth Jae Young Yoo1,5, Do Young Hyeon2,5, Yourae Shin2,5, Soo Min Kim1, Young‑Ah You1,3, Daye Kim4, Daehee Hwang2* & Young Ju Kim1,3* Preterm birth (PTB), defned as birth at less than 37 weeks of gestation, is a major determinant of neonatal mortality and morbidity. Early diagnosis of PTB risk followed by protective interventions are essential to reduce adverse neonatal outcomes. However, due to the redundant nature of the clinical conditions with other diseases, PTB‑associated clinical parameters are poor predictors of PTB. To identify molecular signatures predictive of PTB with high accuracy, we performed mRNA sequencing analysis of PTB patients and full‑term birth (FTB) controls in Korean population and identifed diferentially expressed genes (DEGs) as well as cellular pathways represented by the DEGs between PTB and FTB. By integrating the gene expression profles of diferent ethnic groups from previous studies, we identifed the core T‑cell activation pathway associated with PTB, which was shared among all previous datasets, and selected three representative DEGs (CYLD, TFRC, and RIPK2) from the core pathway as mRNA signatures predictive of PTB. We confrmed the dysregulation of the candidate predictors and the core T‑cell activation pathway in an independent cohort. Our results suggest that CYLD, TFRC, and RIPK2 are potentially reliable predictors for PTB. Preterm birth (PTB) is the birth of a baby at less than 37 weeks of gestation, as opposed to the usual about 40 weeks, called full term birth (FTB)1.